The Dose-Dependent Antiangiogenic Potential of Apixaban: An Experimental Outlook
Abstract
Aim: Direct oral anticoagulants (DOACs) are good alternatives to conventional
medical regimens for the treatment and prevention of thromboembolism. Apixaban
is one of the more popular variations of these newly developed drugs. Aside from its
anticoagulant potential, possible cellular effects remain a topic for future studies. The
object of this study was to investigate the possible antiangiogenic effects of apixaban
in the chorioallantoic membrane (CAM) model.
Method: Drug pellets were prepared at 10-4, 10-5, and 10-6 M concentrations of
apixaban and were placed in the chorioallantoic membrane on the fourth day of
egg incubation. On the eighth day, all vascular densities of the membranes were
compared with a 10-6 M concentration of bevacizumab, which is a known monoclonal,
humanized, vascular endothelial growth-factor inhibitor.
Results: We find that a 10-4 M concentration of apixaban has strong antiangiogenic
potential similar to that of bevacizumab. However, there was moderate antiangiogenic
potential at a lower dose of apixaban (10-5 M, 10-6 M). A comparison of the higher
doses of antiangiogenic potential (10-4 M concentration) with lower doses of
apixaban (10-5 M, 10-6 M) revealed significant statistical differences (p < 0.05).
Conclusion: Our results indicate that a high dose of apixaban has strong
antiangiogenic potential. The exact mechanism of this effect remains unknown.
These pilot results should be confirmed with further studies to obtain an updated
look at DOACs.
Source
Acta Medica AlanyaVolume
6Issue
2URI
https://dergipark.org.tr/tr/download/article-file/2483234https://hdl.handle.net/20.500.12868/1770